Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2038-2044

  Hortobagyi, Gabriel N ^a   Theriault, Richard L ^a   Lipton, Allan ^a   Porter, Lester ^a   Blayney, Douglas ^a   Sinoff, Clive ^a   Wheeler, Helen ^a   Simeone, Joseph F ^a   Seaman, John J ^a   Knight, Robert D ^a   Heffernan, Maika ^a   Mellars, Kathleen ^a   Reitsma, Dirk J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM ION; PAMIDRONIC ACID; PLACEBO;

ANEMIA; ARTHRALGIA; ARTICLE; BONE LESION; BONE METASTASIS; BONE PAIN; BREAST CARCINOMA; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD COMPRESSION; THROMBOCYTOPENIA;

EID: 7144223389     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2038     Document Type: Article

References (20)

1. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493, 1996
2. van Holten-verzantvoort ATM, Kroon HM, Bijvoet OLM, et al: Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498, 1993
3. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone lesions. N Engl J Med 335:1785-1791, 1996
4. Smith IE: Recurrent disease, in Harris JR, Hellman S, Henderson IC (eds): Breast Diseases. Philadelphia, PA. Lippincott, 1987, pp 369-394
5. Jung A, Bizas S, Fleisch H: The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals. Calcif Tissue Res 11:269-280, 1973
6. Fleisch H: Bisphosphonate-history and experimental basis. Bone 8:523-528, 1987 (suppl 1)
7. Flanagan AM, Chambers TJ: Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49:407-415, 1991
8. Lufkin EG, Argueta R, Whitaker MD, et al: Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporos Int 4:320-322, 1994
9. DeGroen PC, Lubbe DF, Hirsch LJ, et al: Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021, 1996
10. Gucalp R, Ritch P, Wiernick PH, et al: Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 10:134-142, 1992
11. Nussbaum SR, Younger J, VandePol CJ, et al: Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med 95:297-304, 1993
12. Beahrs OH, Henson DE, Hutter RVP, (eds): Manual for Staging of Cancer (ed 3). Philadelphia, PA, Lippincott, 1988
13. Spitzer WO, Dobson AJ, Hall J, et al: Measuring the quality of life of cancer patients: A concise Q-index for use by physicians. J Chronic Dis 34:585-597, 1981
14. Tong D, Gillick L, Hendrickson FR: The palliation of symptomatic osseous metastases: Final results of the Study by the Radiation Therapy Oncology Group. Cancer 50:893-899, 1982
15. Hayward JL, Carbone PP, Heuson J-C, et al: Assessment of response to therapy in advanced breast cancer: A project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 39:1289-1294, 1977
16. Hacking A, Gudgeon CA, McNaughton D: Disodium pamidronate (Aredia), as single infusion monotherapy in the treatment of bone metastases from breast cancer, in Bijvoet OLM, Lipton A (eds): Osteoclast Inhibition in the Management of Malignancy: Selected Bone Disorders. Bern, Switzerland, Hogrefs & Huber, 1991, pp 45-53
17. Glover D, Lipton A, Keller A, et al: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer: A dose-seeking study. Cancer 74:2949-2956, 1994
18. Coleman RE, Woll PJ, Miles M, et al: 3-amino-1,1 hydroxypropylidene bisphosphonate (APD) for the treatment of bone metastases from breast cancer. Br J Cancer 58:621-625, 1988
19. Morton AR, Cantrill JA, Pillai GB, et al: Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bis-phosphonate (APD) in patients with breast cancer. Br J Med 297:772-773, 1988
20. Burckhardt P, Thiebaud D, Percy L, et al: Treatment of tumor-induced osteolysis by APD. Rec Res Cancer Res 116:54-66, 1989